Issue 36, 2021

Nanotechnology lights up the antitumor potency by combining chemotherapy with siRNA

Abstract

Nanotechnology-based combination anticancer therapy offers novel approaches to overcome the limitations of single-agent administration. The emerging siRNA technology combined with chemotherapy has shown considerable promise in anticancer therapy. There are three main challenges in the fabrication of siRNA/chemotherapeutic drug co-loaded nanovectors: adequate cargo protection, precise targeted delivery, and site-specific cargo release. This review presents a summary of the nanosystems that have recently been developed for co-delivering siRNA and chemotherapeutic drugs. Their combined therapeutic effects are also discussed.

Graphical abstract: Nanotechnology lights up the antitumor potency by combining chemotherapy with siRNA

Article information

Article type
Review Article
Submitted
20 iyn 2021
Accepted
21 iyl 2021
First published
22 iyl 2021

J. Mater. Chem. B, 2021,9, 7302-7317

Nanotechnology lights up the antitumor potency by combining chemotherapy with siRNA

J. Sun, E. A. Ogunnaike, X. Jiang and Z. Chen, J. Mater. Chem. B, 2021, 9, 7302 DOI: 10.1039/D1TB01379C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements